EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
1.14.13.8 | Homo sapiens | - |
- |
- |
1.14.13.8 | Mus musculus | - |
- |
- |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
1.14.13.8 | kidney | isoform FMO1 | Homo sapiens | - |
1.14.13.8 | kidney | isoforms FMO1 and FMO5 | Mus musculus | - |
1.14.13.8 | liver | isoforms FMO1, FMO3 and FMO5 | Mus musculus | - |
1.14.13.8 | liver | isoforms FMO3 and FMO5 | Homo sapiens | - |
1.14.13.8 | lung | isoform FMO2 | Homo sapiens | - |
1.14.13.8 | lung | isoforms FMO1 and FMO2 | Mus musculus | - |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
1.14.13.8 | (R)-metamphetamine + NADPH + H+ + O2 | substrate of isoform FMO1 | Homo sapiens | (R)-metamphetamine N-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | (S)-metamphetamine + NADPH + H+ + O2 | substrate of isoforms FMO1 and FMO3 | Homo sapiens | (S)-metamphetamine N-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | 5,6-dimethylxanthenone-4-acetic acid + NADPH + H+ + O2 | substrate of isoform FMO3, methyl hydroxylation | Homo sapiens | ? | - |
? | |
1.14.13.8 | 9-hydroxy-5,6-dimethyl-N-(2-(dimethylamino)ethyl)-6H-pyrido(4,3-B)-carbazole-1-carboxamide + NADPH + H+ + O2 | substrate of isoform FMO3 | Homo sapiens | 2-(9-hydroxy-5,6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxamido)-N,N-dimethylethan-1-amine oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | albendazole + NADPH + H+ + O2 | substrate of isoform FMO3 | Homo sapiens | albendazole S-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | almotriptan + NADPH + H+ + O2 | substrate of isoform FMO3 | Homo sapiens | almotriptan N-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | amphetamine + NADPH + H+ + O2 | substrate of isoform FMO3 | Homo sapiens | amphetamine N-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | benzydamine + NADPH + H+ + O2 | substrate of isoforms FMO1 and FMO3 | Homo sapiens | benzydamine N-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | cimetidine + NADPH + H+ + O2 | substrate of isoforms FMO1 and FMO3 | Homo sapiens | cimetidine S-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | clozapine + NADPH + H+ + O2 | substrate of isoform FMO3 | Homo sapiens | clozapine N-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | contezolid + NADPH + H+ + O2 | substrate of isoform FMO5 | Homo sapiens | contezolid N-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | danusertib + NADPH + H+ + O2 | substrate of isoform FMO3 | Homo sapiens | danusertib N-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | dasatinib + NADPH + H+ + O2 | substrate of isoform FMO3 | Homo sapiens | 4-(6-((5-((2-chloro-6-methylphenyl)carbamoyl)thiazol-2-yl)amino)-2-methylpyrimidin-4-yl)-1-(2-hydroxyethyl)piperazine 1-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | deprenyl + NADPH + H+ + O2 | substrate of isoforms FMO1 and FMO3 | Homo sapiens | deprenyl N-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | E-7016 + NADPH + H+ + O2 | substrate of isoform FMO5, Bayer Villiger oxidation | Homo sapiens | ? | - |
? | |
1.14.13.8 | ethionamide + NADPH + H+ + O2 | substrate of isoforms FMO1, FMO2, and FMO3 | Homo sapiens | ethionamide S-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | GSK5182 + NADPH + H+ + O2 | substrate of isoforms FMO1 and FMO3 | Homo sapiens | (Z)-2-(4-(5-hydroxy-1-(4-hydroxyphenyl)-2-phenylpent-1-en-1-yl)phenoxy)-N,N-dimethylethan-1-amine oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | imipramine + NADPH + H+ + O2 | substrate of isoform FMO1 | Homo sapiens | imipramine N-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | itopride + NADPH + H+ + O2 | substrate of isoforms FMO1 and FMO3 | Homo sapiens | itopride N-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | K11777 + NADPH + H+ + O2 | substrate of isoform FMO3 | Homo sapiens | K11777 N-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | L-775,606 + NADPH + H+ + O2 | substrate of isoform FMO3 | Homo sapiens | 4-(3-(5-(4H-1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl)-1-(3-fluorophenethyl)piperazine 1-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | lorcaserin + NADPH + H+ + O2 | substrate of isoform FMO1 | Homo sapiens | lorcaserin N-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | loxapine + NADPH + H+ + O2 | substrate of isoform FMO3 | Homo sapiens | 4-(2-chlorodibenzo[b,f][1,4]oxazepin-11-yl)-1-methylpiperazine 1-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | methimazole + NADPH + H+ + O2 | substrate of isoforms FMO1, FMO2, and FMO3 | Homo sapiens | methimazole S-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | MK-0457 + NADPH + H+ + O2 | substrate of isoforms FMO1 and FMO3 | Homo sapiens | MK-0457 N-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | MK-0767 methyl sulfide + NADPH + H+ + O2 | substrate of isoforms FMO1 and FMO3 | Homo sapiens | ? | - |
? | |
1.14.13.8 | moclobemide + NADPH + H+ + O2 | substrate of isoform FMO3 | Homo sapiens | moclobemide N-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | N,N-diallyltryptamine + NADPH + H+ + O2 | substrate of isoform FMO3 | Homo sapiens | N,N-diallyltryptamine N-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | N-(3R)-1-azabicyclo[2.2.2]oct-3-ylfuro[2,3-c]pyridine-5-carboxamide + NADPH + H+ + O2 | substrate of isoforms FMO1 and FMO3 | Homo sapiens | (R)-3-(furo[2,3-c]pyridine-5-carboxamido)quinuclidine 1-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | N-deacetyl ketoconazole + NADPH + H+ + O2 | substrate of isoform FMO1 | Homo sapiens | N-deacetyl ketoconazole N-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | N-deacetyl ketoconazole + NADPH + H+ + O2 | substrate of isoform FMO3 | Homo sapiens | N-deacetyl ketoconazole N-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | nicotine + NADPH + H+ + O2 | substrate of isoform FMO3 | Homo sapiens | (S)-nicotine N1-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | nomifensine + NADPH + H+ + O2 | substrate of isoforms FMO3 and FMO5 | Homo sapiens | ? | - |
? | |
1.14.13.8 | NSC645809 + NADPH + H+ + O2 | substrate of isoforms FMO1 and FMO3 | Homo sapiens | N,N-diethyl-2-((8-hydroxy-6-oxo-6H-imidazo[4,5,1-de]acridin-5-yl)amino)ethan-1-amine oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | olanzapine + NADPH + H+ + O2 | substrate of isoform FMO3 | Homo sapiens | 1-methyl-4-(2-methyl-10H-benzo[b]thieno[2,3-e][1,4]diazepin-4-yl)piperazine 1-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | olopatadine + NADPH + H+ + O2 | substrate of isoforms FMO1 and FMO3 | Homo sapiens | olopatadine N-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | pargyline + NADPH + H+ + O2 | substrate of isoforms FMO1 and FMO3 | Homo sapiens | pargyline N-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | phospho-sulindac + NADPH + H+ + O2 | substrate of isoforms FMO1, FMO3, and FMO5 | Homo sapiens | ? | - |
? | |
1.14.13.8 | primaquine + NADPH + H+ + O2 | substrate of isoform FMO3 | Homo sapiens | ? | - |
? | |
1.14.13.8 | pyrazolacridine + NADPH + H+ + O2 | substrate of isoform FMO3 | Homo sapiens | pyrazolacridine N-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | quazepam + NADPH + H+ + O2 | substrate of isoform FMO1 | Homo sapiens | 7-chloro-5-(2-fluorophenyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one + NADP+ + H2O | - |
? | |
1.14.13.8 | ranitidine + NADPH + H+ + O2 | substrate of isoforms FMO3 and FMO5, S-oxygenation and N-oxygenation | Homo sapiens | ? | - |
? | |
1.14.13.8 | S-methyl esonarimod + NADPH + H+ + O2 | substrate of isoforms FMO1, FMO3, and FMO5 | Homo sapiens | S-methyl esonarimod S-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | S-methyl N,N-diethyldithiocarbamate + NADPH + H+ + O2 | substrate of isoform FMO1 and FMO3 | Homo sapiens | (diethylnitroryl)(methylsulfanyl)methanethione + NADP+ + H2O | - |
? | |
1.14.13.8 | selenomethionine + NADPH + H+ + O2 | substrate of isoform FMO3 | Homo sapiens | seleno-L-methionine Se-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | SNI-2011 + NADPH + H+ + O2 | substrate of isoform FMO1 | Homo sapiens | SNI-2011 N-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | sulindac sulfide + NADPH + H+ + O2 | substrate of isoforms FMO1 and FMO3 | Homo sapiens | ? | - |
? | |
1.14.13.8 | tamoxifen + NADPH + H+ + O2 | substrate of isoforms FMO1 and FMO3 | Homo sapiens | tamoxifen N-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | tazarotenic acid + NADPH + H+ + O2 | substrate of isoforms FMO1 and FMO3 | Homo sapiens | tazarotenate N-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | TG100435 + NADPH + H+ + O2 | substrate of isoform FMO3 | Homo sapiens | 1-(2-(4-((7-(2,6-dichlorophenyl)-5-methylbenzo[e][1,2,4]triazin-3-yl)amino)phenoxy)ethyl)pyrrolidine 1-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | TG100435 + NADPH + H+ + O2 | substrate of isoform FMO1 | Homo sapiens | ? | - |
? | |
1.14.13.8 | thiacetazone + NADPH + H+ + O2 | substrate of isoforms FMO1, FMO2, and FMO3 | Homo sapiens | thiacetazone S-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | trifluoroperazine + NADPH + H+ + O2 | substrate of isoform FMO3 | Homo sapiens | 2,3,4-trifluoropyridine 1-oxide + NADP+ + H2O | - |
? | |
1.14.13.8 | voriconazole + NADPH + H+ + O2 | substrate of isoforms FMO1 and FMO3 | Homo sapiens | ? | - |
? | |
1.14.13.8 | xanomeline + NADPH + H+ + O2 | substrate of isoforms FMO1 and FMO3 | Homo sapiens | xanomeline N-oxide + NADP+ + H2O | - |
? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
1.14.13.8 | FMO1 | isoform | Mus musculus |
1.14.13.8 | FMO1 | isoform | Homo sapiens |
1.14.13.8 | FMO2 | isoform | Mus musculus |
1.14.13.8 | FMO2 | isoform | Homo sapiens |
1.14.13.8 | FMO3 | isoform | Mus musculus |
1.14.13.8 | FMO3 | isoform | Homo sapiens |
1.14.13.8 | FMO4 | isoform | Mus musculus |
1.14.13.8 | FMO4 | isoform | Homo sapiens |
1.14.13.8 | FMO5 | isoform | Mus musculus |
1.14.13.8 | FMO5 | isoform | Homo sapiens |
EC Number | Cofactor | Comment | Organism | Structure |
---|---|---|---|---|
1.14.13.8 | FAD | - |
Mus musculus | |
1.14.13.8 | FAD | - |
Homo sapiens | |
1.14.13.8 | NADPH | - |
Mus musculus | |
1.14.13.8 | NADPH | - |
Homo sapiens |